MediWound (NASDAQ:MDWD) Releases Earnings Results, Misses Estimates By $0.68 EPS

Key Points

• MediWound reported quarterly earnings of ($1.23) per share, missing the consensus estimate by ($0.68). Despite this, the company's revenue of $5.71 million slightly exceeded analyst expectations of $5.68 million.
• MDWD shares experienced a decline, trading down $0.47 to $18.10, with a significant trading volume of 117,753 shares compared to an average of 68,494.
• Analyst ratings for MediWound vary, with one analyst rating it as a sell and four issuing buy ratings, leading to a consensus rating of "Moderate Buy" and a price target of $32.25.

MediWound (NASDAQ:MDWD - Get Free Report) issued its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.68), Zacks reports. MediWound had a negative return on equity of 96.71% and a negative net margin of 142.18%.The firm had revenue of $5.71 million during the quarter, compared to the consensus estimate of $5.68 million.

MediWound Trading Down 0.3%

NASDAQ:MDWD traded down $0.05 during mid-day trading on Thursday, hitting $17.39. 72,921 shares of the company's stock were exchanged, compared to its average volume of 74,797. MediWound has a one year low of $14.14 and a one year high of $22.50. The business has a fifty day moving average price of $19.34 and a 200 day moving average price of $18.56.

Hedge Funds Weigh In On MediWound

Institutional investors and hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock worth $85,000 after purchasing an additional 999 shares in the last quarter. Rhumbline Advisers raised its holdings in MediWound by 4.4% in the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company's stock worth $176,000 after buying an additional 481 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in MediWound by 69.1% in the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 649 shares during the last quarter. Marshall Wace LLP bought a new position in shares of MediWound in the second quarter worth approximately $317,000. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of MediWound by 104.4% during the second quarter. The Manufacturers Life Insurance Company now owns 26,062 shares of the biopharmaceutical company's stock valued at $505,000 after buying an additional 13,312 shares during the last quarter. 46.83% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

MDWD has been the subject of several analyst reports. Alliance Global Partners initiated coverage on shares of MediWound in a research report on Friday, May 2nd. They set a "buy" rating and a $25.00 price target for the company. Oppenheimer assumed coverage on shares of MediWound in a report on Monday, June 2nd. They set an "outperform" rating and a $34.00 target price for the company. Zacks Research cut MediWound from a "strong-buy" rating to a "hold" rating in a research note on Tuesday. HC Wainwright set a $31.00 target price on MediWound and gave the stock a "buy" rating in a research note on Thursday, May 22nd. Finally, Wall Street Zen cut MediWound from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $32.25.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.